Does Novartis Need A Big Immuno-Oncology Deal? Jimenez Says No

The oncology player missed out on the first round of immune checkpoint inhibition and now some investors are wondering if the pharma needs to buy a rival to catch up. During the company’s second quarter sales call CEO Jimenez insisted Novartis has the internal expertise to execute.